Key result
FFR-guided management of obstructive CAD did not significantly impact all-cause mortality (RR 0.99; 95% CI 0.62-1.60), MI, or unplanned revascularization compared to angiography-guided management.
Why the study?
Randomised controlled trials comparing outcomes after FFR-guided versus angiography-guided management for obstructive CAD have produced conflicting results.
Does an FFR-guided management strategy reduce all-cause mortality, MI, or unplanned revascularisation in patients with obstructive CAD compared to an angiography-guided strategy?
Meta-Analysis (n=5,077)
Does an FFR-guided management strategy reduce all-cause mortality, MI, or unplanned revascularisation in patients with obstructive CAD compared to an angiography-guided strategy?
Relative Risk: 0.99 (95% CI 0.62–1.6)
Absolute Event Rate: 3.5% vs 3.7%
p-value: p=0.98
An FFR-guided management strategy for obstructive CAD does not improve hard clinical outcomes compared to angiography guidance, but it significantly reduces the rate of planned revascularisation.
FFR guidance avoids unnecessary revascularisation without raising mortality or MI risk; reinforces physiology over angiography for procedural decisions in obstructive CAD.
Background and Aims: Randomised controlled trials (RCTs) comparing outcomes after fractional flow reserve (FFR)-guided versus angiography-guided management for obstructive coronary artery disease (CAD) have produced conflicting results. We investigated the efficacy and safety of an FFR-guided versus angiography-guided management strategy among patients with obstructive CAD. Methods: A systematic electronic search of the major databases was performed from inception to September 2022. We included studies of patients presenting with angina or myocardial infarction (MI), managed with medications, percutaneous coronary intervention, or bypass graft surgery. A meta-analysis was performed by pooling the risk ratio (RR) using a random-effects model. The endpoints of interest were all-cause mortality, MI and unplanned revascularisation. Results: Eight RCTs, with outcome data from 5077 patients, were included. The weighted mean follow up was 22 months. When FFR-guided management was compared to angiography-guided management, there was no difference in all-cause mortality [3.5% vs. 3.7%, RR: 0.99 (95% confidence interval (CI) 0.62−1.60), p = 0.98, heterogeneity (I2) 43%], MI [5.3% vs. 5.9%, RR: 0.93 (95%CI 0.66−1.32), p = 0.69, I2 42%], or unplanned revascularisation [7.4% vs. 7.9%, RR: 0.92 (95%CI 0.76−1.11), p = 0.37, I2 0%]. However, the number patients undergoing planned revascularisation by either stent or surgery was significantly lower with an FFR-guided strategy [weighted mean difference: 14 (95% CI 3 to 25)%, p =< 0.001]. Conclusion: In patients with obstructive CAD, an FFR-guided management strategy did not impact on all-cause mortality, MI and unplanned revascularisation, when compared to an angiography-guided management strategy, but led to up to a quarter less patients needing revascularisation.
No takes yet. Share an insight, caveat, or question.
Maznyczka et al. (2022) conducted a meta-analysis in Obstructive coronary artery disease (CAD) (n=5,077). Fractional flow reserve (FFR)-guided management vs. Angiography-guided management was evaluated on All-cause mortality (RR 0.99, 95% CI 0.62-1.60, p=0.98). FFR-guided management of obstructive CAD did not significantly impact all-cause mortality (RR 0.99; 95% CI 0.62-1.60), MI, or unplanned revascularization compared to angiography-guided management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: